Author(s): Fintel StaffFintel reports that Lowenthal Richard E has filed a 13D form with the SEC disclosing ownership of 7,422,432 shares of Silverback Therapeutics Inc (SBTX). This represents 7.9% of the company. On Nov. 8, ARS closed its merger with Silverback. The combined company operates as ARS Pharmaceuticals, Inc. Silverback Therapeutics, Inc. operates as a biotechnology company. The […]